Swiss Group for Clinical Cancer Research (SAKK) – Breast Cancer Project Group
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Swiss Group for Clinical Cancer Research (SAKK) – Breast Cancer Project Group. Clinical trials include: Randomized phase III trial of Herceptin followed by chemotherapy plus Herceptin versus the combination of Herceptin and chemotherapy as palliative treatment in patients with HER2-overexpressing advanced/metastatic breast cancer. Protocol SAKK 22/99Trastuzumab monotherapy followed by the combination of trastuzumab and letrozole in post-menopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to a nonsteroidal aromatase inhibitor. A multicenter two-step phase II trial Protocol SAKK 23/03Phase I–II trial of capecitabine and vinorelbine in elderly patients ( 65 years) with metastatic breast cancer with and without bone involvement. Protocol SAKK 25/99Phase I/II trial of capecitabine with weekly paclitaxel for advanced breast cancer. Protocol SAKK 26/00